Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Nasir Shah, Vlado Perkovic & Sradha Kotwal. (2022) Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. Expert Review of Clinical Pharmacology 15:7, pages 827-842.
Read now
Read now
Pan Liu, Zhengdong Zhang, Jinwu Wang, Xiao Zhang, Xiaoping Yu & Yao Li. (2021) Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies. Bioengineered 12:2, pages 9356-9366.
Read now
Read now
Saurabh B. Ganorkar, Shweta S. Sharma, Mangesh R. Patil, Preeti S. Bobade, Ashish M. Dhote & Atul A. Shirkhedkar. (2021) Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin. Critical Reviews in Analytical Chemistry 51:8, pages 835-847.
Read now
Read now
Maka Siamashvili & Stephen N. Davis. (2021) Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes. Expert Opinion on Pharmacotherapy 22:16, pages 2181-2198.
Read now
Read now
Sirasa Ruangritchankul, Nancye M Peel, Leila Shafiee Hanjani & Leonard C Gray. (2020) The Changes in Medication Prescribing Among the Older People with Cognitive Impairment in the Acute Care Setting. Clinical Interventions in Aging 15, pages 865-876.
Read now
Read now
Articles from other publishers (40)
Michael Moroney, Raj Verma, Makoto Hibino, C. David Mazer, Kim A. Connelly, Andrew T. Yan, Adrian Quan, Hwee Teoh, Subodh Verma & Pankaj Puar. (2023) Impact of diabetes duration on left ventricular mass regression with empagliflozin. ESC Heart Failure 10:3, pages 2134-2140.
Crossref
Crossref
Pranay Wal, Shruti Rathore, Namra Aziz, Yash Kumar Singh & Arpit Gupta. (2023) Aortic stenosis: a review on acquired pathogenesis and ominous combination with diabetes mellitus. The Egyptian Heart Journal 75:1.
Crossref
Crossref
Suvedha Thiagaraj, Twisha S Shukla, Sai Dheeraj Gutlapalli, Hadi Farhat, Huma Irfan, Kanmani Muthiah, Namratha Pallipamu, Sogand Taheri & Safeera Khan. (2023) The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review. Cureus.
Crossref
Crossref
Rania M. Salama, Rodaina H. Ahmed, Alaa A. Farid, Basma A. AbdElSattar, Radwa M. AbdelBaset, Merna E. Youssef & Sara A. El Wakeel. (2023) Gastroprotective effect of dapagliflozin in ethanol-induced gastric lesions in rats: Crosstalk between HMGB1/RAGE/PTX3 and TLR4/MyD88/VEGF/PDGF signaling pathways. International Immunopharmacology 115, pages 109686.
Crossref
Crossref
Vasiliki Chatziravdeli, George I. Lambrou, Athanasia Samartzi, Nikolaos Kotsalas, Eugenia Vlachou, John Komninos & Athanasios N. Tsartsalis. (2023) A Systematic Review and Meta-Analysis of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Type-2 Diabetes. Medicina 59:1, pages 141.
Crossref
Crossref
Sanobia Yousuf & Muhammad Yakoob Ahmedani. (2022) Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:11, pages 102633.
Crossref
Crossref
Nandhidha. RPunnagai. K. (2022) Evaluation of Anti-Inflammatory and Wound Healing Potential of Sodium Glucose Co-Transporter2 (SGLT2) Inhibitors. Research Journal of Pharmacy and Technology, pages 4457-4462.
Crossref
Crossref
Rosanna Maccari & Rosaria Ottanà. (2022) Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives. Journal of Medicinal Chemistry 65:16, pages 10848-10881.
Crossref
Crossref
Min Hee Lee, Ian J. Neeland, Natalia de Albuquerque Rocha, Connor Hughes, Craig R. Malloy & Eunsook S. Jin. (2022) A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat. Metabolism Open 13, pages 100161.
Crossref
Crossref
Harry G. Preuss & Debasis Bagchi. 2022. Nutrition and Functional Foods in Boosting Digestion, Metabolism and Immune Health. Nutrition and Functional Foods in Boosting Digestion, Metabolism and Immune Health
289
307
.
Grace Flower, Ananya Muthukumar, Ciaran O’Hanlon, C. Alex Smith & Michael J. Curtis. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
375
388
.
Anika K. Anam & Silvio E. Inzucchi. 2022. Polycystic Ovary Syndrome. Polycystic Ovary Syndrome
527
553
.
Maria Jose Soler, Conxita Jacobs-Cachá, Manga Motrapu & Hans-Joachim Anders. 2022. Diabetes and Kidney Disease. Diabetes and Kidney Disease
75
104
.
Anna Masajtis-Zagajewska, Tomasz Hołub, Katarzyna Pęczek, Agnieszka Makówka & Michał Nowicki. (2021) Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease. Medicina 57:12, pages 1352.
Crossref
Crossref
Muhammad Afzal, Fahad Al-Abbasi, Muhammad Nadeem, Sultan Alshehri, Mohammed Ghoneim, Syed Imam, Waleed Almalki & Imran Kazmi. (2021) Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians. Metabolites 11:11, pages 794.
Crossref
Crossref
Shun Watanabe, Naoki Sawa, Hiroki Mizuno, Masayuki Yamanouchi, Tatsuya Suwabe, Junichi Hoshino, Keiichi Kinowaki, Kenichi Ohashi, Takeshi Fujii, Yutaka Yamaguchi & Yoshifumi Ubara. (2021) Development of osmotic vacuolization of proximal tubular epithelial cells following treatment with sodium-glucose transport protein 2 inhibitors in type II diabetes mellitus patients-3 case reports. CEN Case Reports 10:4, pages 563-569.
Crossref
Crossref
Yu-Jen Wang, Francesco Paneni, Sokrates Stein & Christian M. Matter. (2021) Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside. Frontiers in Physiology 12.
Crossref
Crossref
Dominik Polterauer, Jason D. Williams, Christopher A. Hone & C. Oliver Kappe. (2021) Telescoped lithiation, C-arylation and methoxylation in flow-batch hybrid toward the synthesis of canagliflozin. Tetrahedron Letters 82, pages 153351.
Crossref
Crossref
Pallavi Prakash Chaurasia, Sagar Dholariya, Fenilkumar Kotadiya & Milav Bhavsar. (2021) A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors. Cureus.
Crossref
Crossref
Laura Mourino-Alvarez, Nerea Corbacho-Alonso, Tamara Sastre-Oliva, Cecilia Corros-Vicente, Jorge Solis, Teresa Tejerina, Luis R. Padial & Maria G. Barderas. (2021) Diabetes Mellitus and Its Implications in Aortic Stenosis Patients. International Journal of Molecular Sciences 22:12, pages 6212.
Crossref
Crossref
Ammar G. Chaudhary, Fadi M. Alreefi & Mohammad A. Aziz. (2021) Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction. CJC Open 3:5, pages 646-657.
Crossref
Crossref
Gabriele Carullo, Sarah Mazzotta, Margarita Vega-Holm, Fernando Iglesias-Guerra, José Manuel Vega-Pérez, Francesca Aiello & Antonella Brizzi. (2021) GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery. Journal of Medicinal Chemistry 64:8, pages 4312-4332.
Crossref
Crossref
振飞 欧. (2021) Empagliflozin in Patients with Type 2 Diabetes: A Meta-Analysis of Cardiovascular Remodeling. Advances in Clinical Medicine 11:02, pages 469-475.
Crossref
Crossref
Shen Chang, Jian-You Chen, Yung-Jen Chuang & Bor-Sen Chen. (2020) Systems Approach to Pathogenic Mechanism of Type 2 Diabetes and Drug Discovery Design Based on Deep Learning and Drug Design Specifications. International Journal of Molecular Sciences 22:1, pages 166.
Crossref
Crossref
Zoltán Papp & Attila Tóth. (2020) New treatment options to reduce heart failure hospitalization. ESC Heart Failure 7:6, pages 3271-3273.
Crossref
Crossref
Matthew A Lee, George McMahon, Ville Karhunen, Kaitlin H Wade, Laura J Corbin, David A Hughes, George Davey Smith, Debbie A Lawlor, Marjo-Riitta Jarvelin & Nicholas J Timpson. (2020) Common variation at 16p11.2 is associated with glycosuria in pregnancy: findings from a genome-wide association study in European women. Human Molecular Genetics 29:12, pages 2098-2106.
Crossref
Crossref
Kenichiro Sato, Tatsuo Mano, Atsushi Iwata & Tatsushi Toda. (2019) Subtype‐Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study. The Journal of Clinical Pharmacology 60:5, pages 629-635.
Crossref
Crossref
Jayanta Dowarah & Ved Prakash Singh. (2020) Anti-diabetic drugs recent approaches and advancements. Bioorganic & Medicinal Chemistry 28:5, pages 115263.
Crossref
Crossref
Rahul P. Kshirsagar, Abhishek A. Kulkarni, Rashmi S. Chouthe, Shahebaaz K. Pathan, Hemant D. Une, G. Bhanuprakash Reddy, Prakash V. Diwan, Siddique Akber Ansari & Jaiprakash N. Sangshetti. (2020) SGLT inhibitors as antidiabetic agents: a comprehensive review. RSC Advances 10:3, pages 1733-1756.
Crossref
Crossref
Tina Schumann, Jörg König, Christine Henke, Diana M. Willmes, Stefan R. Bornstein, Jens Jordan, Martin F. Fromm & Andreas L. Birkenfeld. (2019) Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease. Pharmacological Reviews 72:1, pages 343-379.
Crossref
Crossref
Gita Chawla & Krishna Kr Chaudhary. (2019) A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:3, pages 2001-2008.
Crossref
Crossref
Wesley Nuffer, Briana Williams & Jennifer M. Trujillo. (2019) A review of sotagliflozin for use in type 1 diabetes. Therapeutic Advances in Endocrinology and Metabolism 10, pages 204201881989052.
Crossref
Crossref
Alexander J.M. Brown, Chim Lang, Rory McCrimmon & Allan Struthers. (2017) Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC Cardiovascular Disorders 17:1.
Crossref
Crossref
Natalia G. Vallianou, Eleni Geladari & Christos E. Kazazis. (2017) SGLT-2 inhibitors: Their pleiotropic properties. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11:4, pages 311-315.
Crossref
Crossref
Fernando Gomez-Peralta, Cristina Abreu, Albert Lecube, Diego Bellido, Alfonso Soto, Cristóbal Morales, Miguel Brito-Sanfiel & Guillermo Umpierrez. (2017) Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes. Diabetes Therapy 8:5, pages 953-962.
Crossref
Crossref
Éva Bokor, Sándor Kun, David Goyard, Marietta Tóth, Jean-Pierre Praly, Sébastien Vidal & László Somsák. (2017)
C
-Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential
. Chemical Reviews 117:3, pages 1687-1764.
Crossref
Crossref
Jagdeep S. S. Singh, Amir Fathi, Keeran Vickneson, Ify Mordi, Mohapradeep Mohan, J. Graeme Houston, Ewan R. Pearson, Allan D. Struthers & Chim C. Lang. (2016) Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Tushar Madaan, Mohd. Akhtar & Abul Kalam Najmi. (2016) Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European Journal of Pharmaceutical Sciences 93, pages 244-252.
Crossref
Crossref
. (2016) ▼ Empagliflozin, diabetes and outcomes. Drug and Therapeutics Bulletin 54:7, pages 78-81.
Crossref
Crossref
Xiaoyan Zhong, Dan Lai, Yun Ye, Xuping Yang, Bin Yu & Yilan Huang. (2016) Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 72:6, pages 655-663.
Crossref
Crossref